March 2022

A U.S. astronaut has returned to Earth Wednesday aboard a Russian Soyuz spacecraft after nearly a full year aboard the International Space Station, during which relations between the two space giants plummeted over Russia’s invasion of Ukraine.

The capsule carrying NASA astronaut Mark Vande Hei and Russian cosmonauts, Anton Shkaplerov and Pyotr Dubrov, completed a parachute-assisted landing on the snow-covered steppe of central Kazakhstan, several hours after undocking from the ISS.

For Vande Hei, it ended a U.S. record-breaking stay in space. He was in space for 355 days, breaking the previous record of 340 days set by Scott Kelly in 2016.

NASA says the two countries are continuing to cooperate on the ISS, although Dmitry Rogozin, the head of Russia’s space agency Roscosmos, posted a series of angry tweets shortly after the invasion of Ukraine, suggesting Russia could abandon the ISS and let it plummet back to Earth. He also shared a video showing Russian cosmonauts abandoning Vande Hei on the ISS.

But in a handover ceremony Tuesday before departing the orbital outpost, Shkaplerov, who commanded the latest ISS crew, expressed a more harmonious view.

“People have problems on Earth. On orbit we are one crew,” he said.

The invasion has led to fallout in other areas of cooperation between Moscow and other international partners in space travel. The European Space Agency has postponed an unmanned mission to Mars because it relied on a Russian rocket. And British-based satellite company One Web canceled a series of launches because they also relied on Russian-built rockets, shifting some of them to U.S.-based SpaceX.

Some information for this report was provided by the Associated Press, Reuters and Agence France-Presse.
…

Malaysia’s health ministry is proposing a major initiative to prevent young people from smoking. It’s a bold plan but critics say it has flaws. Dave Grunebaum has the story.
…

The World Health Organization reported a 43 percent spike in deaths from COVID-19 globally last week, while the number of cases continued to fall worldwide.

In its weekly epidemiological report, the WHO said 45,000 deaths attributed to COVID-19 were reported in the week ending March 27, up from 33,000 the week before. That spike follows a week in which deaths declined by 23 percent.

The agency said the increase in deaths is likely driven by changes in the definition of COVID-19 deaths in nations in the Americas such as Chile and the United States, and by retrospective adjustments reported from India in Southeast Asia.

As an example, Chile had the highest number of new deaths, reporting 11,858, a leap of 1,710 percent from the previous week. The United States saw a smaller but still significant increase of 5,367 new deaths, an increase of 8 percent.

While India saw 4,525 of new deaths; it represented an increase of 619 percent. The WHO said those deaths included numbers from Maharashtra state, which initially were not included in last week’s COVID-19 death toll.

While the number of new cases overall fell globally, three European countries — Germany, Italy and France — all saw an increase in new cases from the previous week. While Germany and Italy reported increases of two and six percent respectively, France reported 845,119 new cases – a increase of 45 percent.

The WHO has said repeatedly that COVID-19 case counts are likely a vast underestimate of the coronavirus’ prevalence. The agency also expressed concern that many countries in recent weeks announced plans to drop their comprehensive testing programs and other surveillance measures. They said doing so will cripple efforts to accurately track the spread of the virus.

Some information for this report was provided by the Associated Press.
…

Botswana has become the first country in Africa to approve the use of the Texas-made COVID-19 vaccine Corbevax. Botswana’s president and California biotech company NantWorks made the announcement Monday as they began construction of a plant to produce COVID-vaccines and drugs to fight cancer.

CEO of biotech firm NantWorks Patrick Soon-Shiong announced on Monday that Botswana’s Medicines Regulatory Authority (BOMRA) had approved the Corbevax jab.

He made the announcement at a groundbreaking ceremony for a vaccine and cancer drug production facility, along with Botswana’s President Mokgweetsi Masisi.

“I am pleased to announce, Mr. President, with the incredibly hard work of both the Ministry of Health and BOMRA, today we announce Africa’s first approved vaccine for Africa by Botswana,” Soon-Shiong said.

Corbevax is a patent-free COVID vaccine developed by the Baylor College of Medicine and Texas Children’s Hospital in the United States. It has been used in Bangladesh, India, and Indonesia.

Soon-Shiong said the first consignment would be delivered to Botswana for distribution across Africa.

“This vaccine has been tested and shown to be active in every variant including omicron. I got a commitment this morning that Botswana, effective immediately, will have access to 100 million of these vaccines that you can distribute,” Soon-Shiong said.

The plant, which is expected to be operational by 2026, plans to produce vaccines for COVID and other diseases, as well as cancer treatment drugs.

Masisi said the plant heralds a new dawn for the production of pharmaceuticals on the continent.

“This is particularly noteworthy in the Africa region, which bears a disproportionate disease burden exacerbated limitation of resources and capabilities to address these health challenges. We are determined to dictate a new legacy associated with access to medicines, vaccines and other health technologies,” he said.

Masisi said the facility would help address vaccine inequality in Africa, where less than 20% of the population is fully vaccinated against COVID – two years into the pandemic.

“Disparities in the distribution of vaccines across the world resulted in a lopsided vaccination drive that seriously hampered efforts to effectively contain the COVID-19 worldwide. This problem has been aptly defined as vaccine nationalism. It is therefore our intent, our conviction that the opening of this vaccine manufacturing facility, will go a long way in changing this narrative,” Masisi said.

Botswana’s Health Minister Edwin Dikoloti says the project would also help treat chronic diseases.

“This day marks a new level in our scientific development and advancement. It signifies a new technological breakthrough which will see us as not just a consumer but also a manufacturer of vaccines and other medication that will come out of this magnificent project,” Dikoloti said.

Botswana’s vaccine manufacturing facility will be the second in Africa being built by Soon-Shiong.

In January, the South African-born U.S. billionaire opened a similar facility in Cape Town.
…

The U.S. Food and Drug Administration has authorized a fourth dose of the Pfizer and Moderna COVID-19 vaccines for people 50 and over.

Previously a fourth dose was only authorized for people 12 and up, who are badly immunocompromised.

The U.S. Centers for Disease Prevention and Control will not weigh in on how to implement the FDA’s authorization.

People wanting the fourth shot should only do so at least four months after the previous booster, the FDA said Tuesday.

The FDA’s authorization comes as COVID-19 cases in the U.S. are falling after a winter surge of the omicron variant. 

However, a new subvariant, BA.2, is spreading in Europe and the U.S.

Roughly two-thirds of Americans are fully vaccinated, meaning they’ve had two doses of Pfizer or Moderna or one dose of Johnson & Johnson vaccine. Only half of those eligible have gotten a first booster.

While the vaccines did not stop omicron from circulating widely, health officials say they did help those infected avoid serious illness or death.

The government is also considering authorizing a fourth dose for everyone in the Fall when cases could surge again.

Some information in this report comes from The Associated Press.
…